Dietary interventions for mineral and bone disorder in people with chronic kidney disease

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 9, 2015, Pages

  Liu, Zhuangzhu ^a   Su, Guobin ^a,b   Guo, Xinfeng ^a   Wu, Yifan ^a   Liu, Xusheng ^a   Zou, Chuan ^c   Zhang, Lei ^a   Yang, Qianchun ^d   Xu, Yuan ^a   Ma, Weizhong ^a  

^a GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^d Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CALCIUM ACETATE; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHORUS; ACETIC ACID DERIVATIVE; CALCIUM DERIVATIVE; CALCIUM INTAKE; CALCIUM PHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN INTAKE;

BONE DISEASE; BONE METABOLISM; BONE MINERAL; BREAD; CALCIUM BLOOD LEVEL; CALCIUM ENRICHED BREAD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIET SUPPLEMENTATION; DIET THERAPY; ENZYME ACTIVITY; FRACTURE; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; LOW FAT DIET; MINERAL DEFICIENCY; MINERAL METABOLISM; MORTALITY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PRIORITY JOURNAL; PROTEIN INTAKE; PROTEIN RESTRICTION; REVIEW; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; ADMINISTRATION AND DOSAGE; BLOOD; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM INTAKE; COMPLICATION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACETATES; ALKALINE PHOSPHATASE; BONE DENSITY; BONE DISEASES, METABOLIC; BREAD; CALCIUM; CALCIUM COMPOUNDS; CALCIUM PHOSPHATES; CALCIUM, DIETARY; DIETARY PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHOSPHORUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84958146075     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010350.pub2     Document Type: Review

References (63)

1. Babarykin D, Adamsone I, Amerika D, Spudass A, Moisejev V, Berzina N, et al. Calcium-enriched bread for treatment of uremic hyperphosphatemia. Journal of Renal Nutrition 2004;14(3):149-56. [MEDLINE: 15232793]
2. Bunio A, Kwiecinski R, Steciwko A, Migas A. Effect of lipid lowering treatment on direct markers of bone metabolism in hemodialysis patients [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:320-1. [CENTRAL: CN-00509112]
3. Di Iorio BR, Bellizzi V, Minutolo R, De Nicola L, Iodice C, Conte G. Supplemented very low-protein diet in advanced CRF: is it money saving?. Kidney International 2004;65(2):742. [MEDLINE: 14717953]
4. Di Iorio BR, Minutolo R, De Nicola L, Bellizzi V, Catapano F, Iodice C, et al. Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure. Kidney International 2003;64(5):1822-8. [MEDLINE: 14531817]
5. Herselman MG, Albertse EC, Lombard CJ, Swanepoel CR, Hough FS. Supplemented low-protein diets - are they superior in chronic renal failure?. South African Medical Journal (Suid Afrikaanse Tydskrif vir Geneeskunde) 1995;85(5):361-5. [MEDLINE: 7638685]
6. Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clinical Journal of the American Society of Nephrology: CJASN 2013;8(6):1009-18. [MEDLINE: 23471131]
7. Isakova T, Barchi-Chung A, Enfield G, Smith KT, Vargas GS, Houston J, et al. Effects of dietary phosphate restriction and lanthanum carbonate on fibroblast growth factor 23 in chronic kidney disease [abstract no: FR-OR068]. Journal of the American Society of Nephrology 2012;23:45A.
8. Li H, Long Q, Shao C, Fan H, Yuan L, Huang B, et al. Effect of short-term low-protein diet supplemented with keto acids on hyperphosphatemia in maintenance hemodialysis patients. Blood Purification 2011;31(1-3):33-40. [MEDLINE: 21135547]
9. Garcia-Mena M, Caverni A, Miguel Lou L, Gimeno JA, Perez J, Alvarez R, et al. Dietary intervention focused on phosphate intake in hemodialysis patients with hyperphosphoremia [abstract]. NDT Plus 2010;3:iii512. [EMBASE: 70484082]
10. Lou LM, Caverni A, Gimeno JA, Moreno R, Perez J, Alvarez R, et al. Dietary intervention focused on phosphate intake in hemodialysis patients with hyperphosphoremia. Clinical Nephrology 2012;77(6):476-83. [MEDLINE: 22595390]
11. Sharma M, Rao M, Jacob S, Jacob CK. A controlled trial of intermittent enteral nutrient supplementation in maintenance hemodialysis patients. Journal of Renal Nutrition 2002;12(4):229-37. [MEDLINE: 12382215]
12. Sullivan C, Sayre SS, Leon JB, Machekano R, Love TE, Porter D, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 2009;301(6):629-35. [MEDLINE: 19211470]
13. Tan KS. The effect of slow release nicotinic acid on serum phosphorus in dialysis patients. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000500954 (accessed 27 August 2015).
14. Ambrus C, Marton A, Almasi C, Berta K, Deak G, Horvath C, et al. Native vitamin D supplementation may slow down bone loss in patients on maintenance hemodialysis [abstract no: SU-FC219]. Journal of the American Society of Nephrology 2003;14:48A. [CENTRAL: CN-00550502]
15. Marton A, Ambrus C, Almasi C, Berta k, Csaktornyai E, Vezekenyi Z, et al. Effects of native Vitamin D supplementation in patients on maintenance hemodialysis [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):146. [CENTRAL: CN-00446637]
16. Ashurst Ide B, Dobbie H. A randomized controlled trial of an educational intervention to improve phosphate levels in hemodialysis patients. Journal of Renal Nutrition 2003;13(4):267-74. [MEDLINE: 14566763]
17. Cheng SC, Young DO, Delmez JA, Coyne DW. The effect of oral niacinamide on serum phosphorus levels in hemodialysis patients [abstract no: PUB430]. Journal of the American Society of Nephrology 2007;18(Abstracts):924A.
18. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(4):1131-38. [MEDLINE: 18385391]
19. Chertow GM. Slowing the progression of vascular calcification in hemodialysis. Journal of the American Society of Nephrology 2003;14(Suppl 4):S310-4.
20. Clark B, Patel A, Groves-Seaman L, Palombine J, Marcus R. Strategies to improve phosphorus control in patients with chronic severe hyperphosphatemia [abstract]. American Journal of Kidney Diseases 2010;55(4):A49. [EMBASE: 70124728]
21. Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clinical Journal of the American Society of Nephrology: CJASN 2011;6(2):257-64. [MEDLINE: 21183586]
22. Morey B, Walker R, Davenport A. More dietetic time, better outcome? A randomized prospective study investigating the effect of more dietetic time on phosphate control in end-stage kidney failure haemodialysis patients. Nephron 2008;109(3):c173-80. [MEDLINE: 18663331]
23. Wang Y. Effect of kidney yin/yang replenishment on bone metabolism in patients with renal osteodystrophy. www.clinicaltrials.gov/ct2/show/NCT01665651 (accessed 27 August 2015).
24. Olivero J, Garney P, Armentrout B, Mays L, Holland R. Niacin used for the treatment of hyperphosphatemia in hemodialysis patients [abstract no: F-PO104]. Journal of the American Society of Nephrology 2006;17(Abstracts):358A.
25. Padhi D, SalfiM, Harris RZ. The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals. American Journal of Therapeutics 2007;14(3):235-40. [MEDLINE: 17515696]
26. Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney International 2012;81(11):1116-22. [MEDLINE: 22297674]
27. Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Peritoneal Dialysis International 2009;29(5):562-7. [MEDLINE: 19776051]
28. Akizawa T, Tsuruta Y, Okada Y, Miyauchi Y, Suda A, Kasahara H, et al. Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial. BMC Nephrology 2014;15(1):98. [MEDLINE: 24968790]
29. Block GA, Persky MS, Shamblin BM, Baltazar MF, Singh B, Sharma A, et al. Effect of salivary phosphate-binding chewing gum on serum phosphorus in chronic kidney disease. Nephron 2013;123(1-2):93-101. [MEDLINE: 23797006]
30. Garini G, Arisi L, Borrini A, Fiaccadori E, Guariglia A, Magnati G, et al. Adherence to dietetic treatment, the nutritional metabolic status and the progression of chronic kidney failure. Annali Italiani di Medicina Interna 1992;7(2):71-7. [MEDLINE: 1467127]
31. Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney International 2013;83(5):959-66. [MEDLINE: 23254903]
32. Karavetian M, De Vries N, Elzein H. Nutritional intervention for management of osteodystrophy (NIMO) program in hemodialysis patients, Lebanon and baseline data [abstract no: 107]. Kidney Research & Clinical Practice 2012;31(2):A43. [EMBASE: 70814816]
33. Karavetian M, Ghaddar S. Nutritional education for the management of osteodystrophy (NEMO) in patients on haemodialysis: a randomised controlled trial. Journal of Renal Care 2013;39(1):19-30. [MEDLINE: 23176599]
34. Saade A, Karavetian M, ElZein H, De Vries N. Nutritional education for management of osteodystrophy (NEMO) trial: Impact on quality of life [abstract]. Nephrology Dialysis Transplantation 2013;28(Suppl 1):i119. [EMBASE: 71075331]
35. Levin A. Study of dietary phosphate and mineral homeostasis in early chronic kidney disease. www.clinicaltrials.gov/ct2/show/NCT00755690 (accessed 27 August 2015).
36. Riccio E. Effects of the 6-point diet on the metabolic control, the compliance and the nutritional status of CKD Patients Stage 3b-5. www.clinicaltrials.gov/ct2/show/NCT01865526 (accessed 27 August 2015).
37. Liu W. Study of vitamin D2 virus 1, 25(OH)2-vitamin D3 and normal protein diet virus low protein diet in the treatment of CKD-MBD and malnutrition for progressive CKD. www.clinicaltrials.gov/ct2/show/NCT02005302 (accessed 27 August 2015).
38. Bellorin-Font E, Ambrosoni P, Carlini RG, Carvalho AB, Correa-Rotter R, Cueto-Manzano A, et al. Clinical Practice Guidelines for the Prevention, Diagnosis, Evaluation and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease (CKD-MBD) in Adults. Nefrología 2013;33 Suppl 1:1-28. [MEDLINE: 23629678]
39. Cianciaruso B, Pota A, Pisani A, Torraca S, Annecchini R, Lombardi P, et al. Metabolic effects of two low protein diets in chronic kidney disease stage 4-5--a randomized controlled trial. Nephrology Dialysis Transplantation 2008;23(2):636-44. [MEDLINE: 17981885]
40. Cupisti A, Gallieni M, Rizzo MA, Caria S, Meola M, Bolasco P. Phosphate control in dialysis. International Journal of Nephrology & Renovascular Disease 2013;6:193-205. [MEDLINE: 24133374]
41. Di Iorio B, Di Micco L, Torraca S, Sirico ML, Russo L, Pota A, et al. Acute effects of very-low-protein diet on FGF23 levels: a randomized study. Clinical Journal of The American Society of Nephrology: CJASN 2012;7(4):581-7. [MEDLINE: 22362063]
42. Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001892.pub3]
43. Goldsmith DJ, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrology Dialysis Transplantation 2010;25:3823-31. [DOI: 10.1093/ndt/gfq513]
44. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
45. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
46. Johnson DW. Dietary protein restriction as a treatment for slowing chronic kidney disease progression: the case against. Nephrology 2006;11(1):58-62. [MEDLINE: 16509934]
47. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney International - Supplement 2009, (113):S1-130. [MEDLINE: 19644521]
48. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease In chronic kidney disease. American Journal of Kidney Diseases 2003;42(4 Suppl 3):S1-201. [MEDLINE: 14520607]
49. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. New England Journal of Medicine 1994;330(13):877-84. [MEDLINE: 8114857]
50. Komaba H, Tanaka M, Fukagawa M. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Internal Medicine 2008;47(11):989-94. [MEDLINE: 18520108]
51. Kuro-O M. Phosphate and Klotho. Kidney International - Supplement 2011, (121):S20-3. [MEDLINE: 21346722]
52. McCrory WW, Gertner JM, Burke FM, Pimental CT, Nemery RL. Effects of dietary phosphate restriction In children with chronic renal failure. Journal of Pediatrics 1987;111(3):410-2. [MEDLINE: 3625412]
53. Mejía N, Roman-García P, Miar AB, Tavira B, Cannata-Andía JB. Chronic kidney disease-mineral and bone disorder: a complex scenario. Nefrologia 2011;31(5):514-9. [MEDLINE: 21959717]
54. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 2006;69(11):1945-53. [MEDLINE: 16641930]
55. Moe SM, Drüeke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral bone disorder: a new paradigm. Advances In Chronic Kidney Disease 2007;14(1):3-12. [MEDLINE: 17200038]
56. Navaneethan S, Palmer SC, Schreiber MJ, Strippoli GF. Weighing the evidence for treatment of chronic kidney disease mineral and bone disorder. Nephrology 2009;14(4):363-6. [MEDLINE: 19563376]
57. Pelletier S, Roth H, Bouchet JL, Drüeke T, London G, Fouque D, et al. Mineral and bone disease pattern in elderly haemodialysis patients. Nephrology Dialysis Transplantation 2010;25(9):3062-70. [MEDLINE: 20237058]
58. Razzaque MS. Osteo-renal regulation of systemic phosphate metabolism. IUBMB Life 2011;63(4):240-7. [MEDLINE: 21438115]
59. Slatopolsky E, Bricker NS. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism In chronic renal disease. Kidney International 1973;4(2):141. [MEDLINE: 4355426]
60. Soroka N, Silverberg DS, Greemland M, Birk Y, Blum M, Peer G, et al. Comparison of a vegetable-based (soya) and an animal-based low-protein diet in predialysis chronic renal failure patients. Nephron 1998;79(2):173-80. [MEDLINE: 9647497]
61. Takeda E, Yamamoto H, Nishida Y, Sato T, Sawada N, Taketani Y. Phosphate restriction In diet therapy. Contributions to Nephrology 2007;155:113-24. [MEDLINE: 17369719]
62. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases 2008;52(3):519-30. [MEDLINE: 1851498]
63. Liu Z, Su G, Guo XF, Wu Y, Liu X, Zou C, et al. Dietary interventions for mineral and bone disorder in people with chronic kidney disease. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD010350]